{"transactions":[{"id":868358,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2026-03-03T23:08:04.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":11.52,"expiration_date":"2036-02-27","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001878290-26-000004","document":"wk-form4_1772579282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000187829026000004/wk-form4_1772579282.xml","form_type":"4"}},{"id":944789,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2026-01-08T02:31:18.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":5000,"derivative":{"underlying":"Common Shares","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001878290-26-000002","document":"wk-form4_1767839475.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000187829026000002/wk-form4_1767839475.xml","form_type":"4"}},{"id":944788,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2026-01-08T02:31:18.000Z","date":"2026-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":1117,"price":9.93,"value":11091.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":66978,"source":{"system":"sec-edgar","filing":"0001878290-26-000002","document":"wk-form4_1767839475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000187829026000002/wk-form4_1767839475.xml","form_type":"4"}},{"id":944787,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2026-01-08T02:31:18.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68095,"source":{"system":"sec-edgar","filing":"0001878290-26-000002","document":"wk-form4_1767839475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000187829026000002/wk-form4_1767839475.xml","form_type":"4"}},{"id":996027,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-11-18T12:29:10.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":8.5159,"value":144770.3,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.4950 - $8.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001878290-25-000004","document":"wk-form4_1763468947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000187829025000004/wk-form4_1763468947.xml","form_type":"4"}},{"id":1308350,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2025-01-08T01:50:01.000Z","date":"2025-01-05","kind":"exercise","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":7500,"derivative":{"underlying":"Common Shares","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001935979-25-000004","document":"wk-form4_1736300995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000004/wk-form4_1736300995.xml","form_type":"4"}},{"id":1308349,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2025-01-08T01:50:01.000Z","date":"2025-01-05","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":10000,"derivative":{"underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001935979-25-000004","document":"wk-form4_1736300995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000004/wk-form4_1736300995.xml","form_type":"4"}},{"id":1308348,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2025-01-08T01:50:01.000Z","date":"2025-01-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":38.64,"expiration_date":"2035-01-05","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001935979-25-000004","document":"wk-form4_1736300995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000004/wk-form4_1736300995.xml","form_type":"4"}},{"id":1308347,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-01-08T01:50:01.000Z","date":"2025-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":1117,"price":38.64,"value":43160.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the \"ESPP\") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024."}],"balance_after":65051,"source":{"system":"sec-edgar","filing":"0001935979-25-000004","document":"wk-form4_1736300995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000004/wk-form4_1736300995.xml","form_type":"4"}},{"id":1308346,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-01-08T01:50:01.000Z","date":"2025-01-05","kind":"exercise","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the \"ESPP\") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024."}],"balance_after":66168,"source":{"system":"sec-edgar","filing":"0001935979-25-000004","document":"wk-form4_1736300995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000004/wk-form4_1736300995.xml","form_type":"4"}},{"id":1688403,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-01-05T01:08:17.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on January 2, 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":27500,"derivative":{"exercise_price":41.93,"expiration_date":"2034-01-02","underlying":"Common Shares","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001562180-24-000287","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000156218024000287/primarydocument.xml","form_type":"4"}},{"id":1748810,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-11-07T01:33:20.000Z","date":"2023-11-02","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on November 2, 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":22500,"derivative":{"exercise_price":29.49,"expiration_date":"2033-11-02","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-23-007578","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935979/000156218023007578/primarydocument.xml","form_type":"4"}},{"id":2147619,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":29.58,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147618,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":960,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":31.62,"expiration_date":"2028-11-20","underlying":"Common Shares","underlying_shares":960},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147617,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1915,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":31.62,"expiration_date":"2028-11-20","underlying":"Common Shares","underlying_shares":1915},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147616,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":52.44,"expiration_date":"2029-12-05","underlying":"Common Shares","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147615,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":4602,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":81.32,"expiration_date":"2031-01-06","underlying":"Common Shares","underlying_shares":4602},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147614,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":2398,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":81.32,"expiration_date":"2031-01-06","underlying":"Common Shares","underlying_shares":2398},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147613,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":69.68,"expiration_date":"2031-05-06","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147612,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":9225,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":9225},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147611,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":775,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":775},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147610,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147609,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147608,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147607,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147606,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2147605,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-10-03T20:24:25.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":4292,"price":148.5,"value":637362.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each common share of the Issuer (each, a \"Common Share\") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-006952","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022006952/primarydocument.xml","form_type":"4"}},{"id":2273697,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-12T20:58:58.000Z","date":"2022-05-10","kind":"exercise","acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in four equal installments on December 5, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date."}],"balance_after":2250,"derivative":{"exercise_price":53.76,"expiration_date":"2029-12-05","underlying":"Common Shares","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001562180-22-004014","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022004014/primarydocument.xml","form_type":"4"}},{"id":2273696,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-05-12T20:58:58.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":4200,"price":141.5,"value":594300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4065,"source":{"system":"sec-edgar","filing":"0001562180-22-004014","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022004014/primarydocument.xml","form_type":"4"}},{"id":2273695,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-05-12T20:58:58.000Z","date":"2022-05-10","kind":"exercise","acquired":true,"shares":2250,"price":53.76,"value":120960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":8265,"source":{"system":"sec-edgar","filing":"0001562180-22-004014","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022004014/primarydocument.xml","form_type":"4"}},{"id":2427926,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"exercise","acquired":false,"shares":1920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date."}],"balance_after":2875,"derivative":{"exercise_price":32.42,"expiration_date":"2028-11-20","underlying":"Common Shares","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427925,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option vest in four equal installments on December 5, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date."}],"balance_after":4500,"derivative":{"exercise_price":53.76,"expiration_date":"2029-12-05","underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427924,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":3520,"price":119.3694,"value":420180.288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.84 - $119.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":6015,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427923,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":500,"price":118.048,"value":59024.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 - $118.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":9535,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427922,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":2159,"price":116.0189,"value":250484.8051,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.39 - $116.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":10035,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427921,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":3196,"price":114.9293,"value":367314.0428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.30 - $115.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":12194,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427920,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"exercise","acquired":true,"shares":1920,"price":32.42,"value":62246.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":15390,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2427919,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-24T06:01:39.000Z","date":"2022-01-19","kind":"exercise","acquired":true,"shares":3750,"price":53.76,"value":201600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":13470,"source":{"system":"sec-edgar","filing":"0001562180-22-000587","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000587/primarydocument.xml","form_type":"4"}},{"id":2436978,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-12T21:12:52.000Z","date":"2022-01-10","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 4,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":1000,"derivative":{"underlying":"Common Shares","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001562180-22-000440","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000440/primarydocument.xml","form_type":"4"}},{"id":2436977,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-12T21:12:52.000Z","date":"2022-01-10","kind":"tax_withholding","acquired":false,"shares":464,"price":128.87,"value":59795.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":9720,"source":{"system":"sec-edgar","filing":"0001562180-22-000440","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000440/primarydocument.xml","form_type":"4"}},{"id":2436976,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-12T21:12:52.000Z","date":"2022-01-10","kind":"exercise","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10184,"source":{"system":"sec-edgar","filing":"0001562180-22-000440","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000440/primarydocument.xml","form_type":"4"}},{"id":2440317,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-07","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The reporting person was granted 5,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. 100% of these restricted share units are generally subject to settlement in 10 equal annual installments after separation from service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":4000,"derivative":{"underlying":"Common Shares","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440316,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The reporting person was granted 5,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. 100% of these restricted share units are generally subject to settlement in 10 equal annual installments after separation from service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":5000,"derivative":{"underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440315,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":128.87,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440314,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 3,500 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":1750,"derivative":{"underlying":"Common Shares","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440313,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":522,"price":128.87,"value":67270.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":9184,"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440312,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-07","kind":"exercise","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9706,"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440311,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-06","kind":"tax_withholding","acquired":false,"shares":409,"price":123.86,"value":50658.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":8706,"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2440310,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2022-01-07T21:18:31.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9115,"source":{"system":"sec-edgar","filing":"0001562180-22-000356","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218022000356/primarydocument.xml","form_type":"4"}},{"id":2461338,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2021-12-22T21:51:47.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":1915,"price":123.84,"value":237153.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":8240,"source":{"system":"sec-edgar","filing":"0001562180-21-007868","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007868/primarydocument.xml","form_type":"4"}},{"id":2494382,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Restricted Share Unit Award","published_at":"2021-11-26T16:26:46.000Z","date":"2021-11-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."}],"balance_after":15000,"derivative":{"underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-21-007298","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007298/primarydocument.xml","form_type":"4"}},{"id":2494381,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-26T16:26:46.000Z","date":"2021-11-23","kind":"exercise","acquired":false,"shares":1915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date."}],"balance_after":4795,"derivative":{"exercise_price":32.42,"expiration_date":"2028-11-20","underlying":"Common Shares","underlying_shares":1915},"source":{"system":"sec-edgar","filing":"0001562180-21-007298","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007298/primarydocument.xml","form_type":"4"}},{"id":2494380,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2021-11-26T16:26:46.000Z","date":"2021-11-26","kind":"tax_withholding","acquired":false,"shares":2318,"price":115.55,"value":267844.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":10155,"source":{"system":"sec-edgar","filing":"0001562180-21-007298","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007298/primarydocument.xml","form_type":"4"}},{"id":2494379,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2021-11-26T16:26:46.000Z","date":"2021-11-26","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12473,"source":{"system":"sec-edgar","filing":"0001562180-21-007298","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007298/primarydocument.xml","form_type":"4"}},{"id":2494378,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63393,"kind":"person","name":"Clark George C.","position":1,"cik":"0001878290","reported_name":"Clark George C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2021-11-26T16:26:46.000Z","date":"2021-11-23","kind":"exercise","acquired":true,"shares":1915,"price":32.42,"value":62084.3,"ownership":{"direct":true},"balance_after":7473,"source":{"system":"sec-edgar","filing":"0001562180-21-007298","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878290/000156218021007298/primarydocument.xml","form_type":"4"}}]}